Back to Index
Casey O'Connell, MD
Associate Professor of Clinical Medicine, Lawrence and Janice Kelly Chair in Hematology
1441 Eastlake Ave. Health Sciences Campus Los Angeles
+1 323 865 3950


Upon graduating from the George Washington University School of Medicine, Dr. O’Connell came to USC to complete residency and internship training and has maintained an affiliation with the Keck School of Medicine. Dr. O’Connell has achieved accolades at every level, including graduating medical school with distinction, Junior Resident of the Year honor, Senior Resident of the Year honor and a Fellow teaching award.

Dr. O’Connell is actively involved in clinical research in the areas of blood clotting disorders and leukemia. She has published several papers in the area of cancer-related thrombosis.


Keck School of Medicine: Master Teacher Distinction, 2013

LAC+USC Medical Center: Medical Staff Leadership Recognition Award, 2013

Keck School of Medicine : Outstanding Year I Teaching Award, 2012-2013

Keck School of Medicine: Best Year I System, 2011-2012

Keck School of Medicine : Outstanding Year I Teaching Award, 2008-2009

Division of Hematology, USC: Fellow Research Award, 2006-2007

Division of Hematology, USC: Fellow Teaching Award, 2004-2005

USC Department of Medicine: Brautbar Teaching Award, 2003-2004

USC Department of Medicine: Senior Resident of the Year, 2003-2004

Keck School of Medicine: Outstanding Resident Teaching Award, 2003

George Washington University Department of Medicine: Jorge C. Rios Award in Internal Medicine, 2001

Laszlo M Tauber Scholarship

George Washington University School of Medicine: William Beaumont Medical Research Honor Society, 1998


. View in: PubMed

Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome. Acta Haematol. 2017 Sep 02; 138(3):129-137. View in: PubMed

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 Aug 24. View in: PubMed

Management of the Incidental Pulmonary Embolism. AJR Am J Roentgenol. 2017 Mar; 208(3):485-488. View in: PubMed

Initiating a Standard Venous Thromboembolism Prophylaxis Order Set Designed to Improve Patient Outcomes at Los Angeles County+University of Southern California. Am Surg. 2016 Oct; 82(10):1000-1004. View in: PubMed

Correction of refractory thrombocytopenia and anemia following withdrawal of extended release niacin. Am J Hematol. 2016 Jul; 91(7):E318. View in: PubMed

Incidental venous thromboembolic events in cancer patients: what we know in 2016. Thromb Res. 2016 Apr; 140 Suppl 1:S18-20. View in: PubMed

Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy. Ann Hematol. 2016 Apr; 95(5):733-8. View in: PubMed

Emerging treatment options for myelofibrosis: focus on pacritinib. Onco Targets Ther. 2016; 9:2655-65. View in: PubMed

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1099-1110. View in: PubMed

How I treat incidental pulmonary embolism. Blood. 2015 Mar 19; 125(12):1877-82; quiz 2009. View in: PubMed

Incidentally found pulmonary embolism: what's the clinician to do? Hematology Am Soc Hematol Educ Program. Incidentally found pulmonary embolism: what's the clinician to do? Hematology Am Soc Hematol Educ Program. 2015; 2015:197-201. View in: PubMed

Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. Hum Pathol. 2014 Nov; 45(11):2183-91. View in: PubMed

Approach to the management of incidental venous thromboembolic events in patients with cancer. J Natl Compr Canc Netw. 2014 Nov; 12(11):1557-60. View in: PubMed

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2014 Jun 20; 32(18):1919-26. View in: PubMed

Experience with pegylated interferon a-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica. 2012 Oct; 97(10):1570-3. View in: PubMed

Unsuspected pulmonary embolism: impact on mortality among cancer patients. Curr Opin Pulm Med. 2012 Sep; 18(5):406-9. View in: PubMed

Treating venous thromboembolism in patients with cancer. Expert Rev Hematol. 2012 Apr; 5(2):201-9. View in: PubMed

Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism. J Clin Oncol. 2011 Nov 01; 29(31):4208-9; author reply 4209-10. View in: PubMed

Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost. 2011 Feb; 9(2):305-11. View in: PubMed

A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation. Epigenetics. 2010 Nov-Dec; 5(8):750-7. View in: PubMed

Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond. Expert Rev Hematol. 2008 Dec; 1(2):175-82. View in: PubMed

Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 2006 Oct 20; 24(30):4928-32. View in: PubMed

Managing anemia in HIV-positive women. Womens Health (Lond). 2006 Jan; 2(1):159-65. View in: PubMed

Powered bySC CTSI